OpenPayer

Effective 6/15/2026, this Cigna Medical Coverage Policy (0158) adds and consolidates explicit coverage criteria for FDA‑approved implantable upper airway hypoglossal nerve stimulation devices for obstructive sleep apnea (OSA). The policy specifies device‑level indications and separate age/AHI/BMI thresholds for the Inspire Upper Airway Stimulation System and the Genio® System 2.1, and it explicitly states pediatric Down syndrome criteria and remote replacement coverage. The document integrates FDA PMA conditions into medical necessity language (e.g., absence of complete concentric collapse on DISE; central + mixed apneas ≤ 25% of total AHI).

The revision lists detailed device-specific eligibility: Inspire adults ≥18 years with AHI 15–100 and BMI ≤40; Genio® System 2.1 adults ≥22 years with AHI 15–65 and BMI ≤32; Inspire pediatric age 13–18 years with Down syndrome and AHI >10 and <50 with BMI ≤95th percentile. It also clarifies PAP failure/intolerance definitions and makes DISE indications explicit for adults and adolescents with Down syndrome. Additionally, non‑coverage guidance for off‑the‑shelf remote batteries and criteria for remote replacement (malfunction + out of warranty) are included.

Cigna defines medical necessity for an FDA‑approved implantable hypoglossal nerve stimulation device in adults when all listed criteria are met: age/AHI/BMI per device, central + mixed apneas ≤25% of total AHI, absence of complete concentric collapse at the soft palate level on drug‑induced sleep endoscopy (DISE), and documented PAP treatment failure or intolerance (or unwillingness to use PAP). PAP failure is described as inability to eliminate OSA (residual AHI ≥15), while PAP intolerance includes inability to use PAP >4 hours per night, 5 nights per week, or unwillingness after trial. The policy points to PSG/HSAT criteria elsewhere in the sleep guideline for pre‑ and post‑implant testing.

The policy incorporates FDA labeling details for the Inspire and Genio® systems into the coverage language, aligning Cigna’s medical necessity conditions with PMA indications (including DISE findings and central apnea limits). It also references procedural CPT codes tied to DISE and implantation, such as 42975 for DISE and 64582 for open implantation of hypoglossal nerve neurostimulator array and pulse generator.

The policy establishes a specific pathway for pediatric individuals with Down syndrome. An FDA‑approved implantable hypoglossal nerve stimulation device is considered medically necessary for pediatric Down syndrome patients when all criteria are met: device‑specific age/AHI/BMI limits, absence of complete concentric collapse at the soft palate on DISE, contraindication or ineffective adenotonsillectomy, confirmed PAP failure or intolerance despite compliance efforts, and consideration of all other alternative/adjunct therapies. Separately, for the Inspire system the policy explicitly lists an adolescent age range of 13–18 years with AHI >10 and <50 and BMI ≤95th percentile.

The document summarizes pediatric evidence (e.g., Yu et al., Liu et al.) showing case series and cohort data supporting improvements in AHI and QOL in adolescents with Down syndrome, but it notes the lack of randomized controlled trials. The policy therefore conditions pediatric coverage on the same DISE and PAP‑failure prerequisites emphasized for adults and references the FDA pediatric labeling caveats (e.g., limited data for BMI >95th percentile).

The policy incorporates FDA PMA nuances and device manuals into coverage language and highlights device‑specific contraindications and unknowns. For Inspire, Cigna mirrors the PMA expansion allowing AHI up to 100 and BMI warning up to 40, while noting the PMA language that BMI >40 was not well studied. For Genio® System 2.1, the policy reflects the August 8, 2025 PMA limits (age ≥22, AHI 15–65, BMI ≤32) and the manufacturer’s manual exclusions (e.g., age <22 or >75, BMI >32, CCC at soft palate). The policy explicitly requires absence of complete concentric collapse (CCC) on DISE as a medical necessity criterion.

The General Background and Literature Review sections are summarized in policy text: evidence is primarily cohorts, registries, and nonrandomized studies (e.g., STAR trial, systematic reviews by Kim 2024 and Wollny 2024). Cigna cites the STAR trial outcomes (median AHI drop from 29.3 to 9.0 at 12 months; 60% achieving ≥50% AHI reduction) and safety syntheses (low mortality, device survival ~0.9834 at 60 months, revision and explantation rates noted). These evidence summaries support a position of coverage for select patients intolerant of or failing PAP.

The policy clarifies coverage details for ancillary device components and diagnostic procedures. The replacement of an external remote for an FDA‑approved implantable hypoglossal nerve stimulator is considered medically necessary when documentation shows the remote is malfunctioning and is out of warranty. Conversely, off‑the‑shelf batteries used in the remote are generally considered not medically necessary because they are not primarily medical in nature.

Diagnostic and procedural coding and coverage are referenced: 42975 for DISE (dynamic flexible diagnostic endoscopy) is included among listed CPT/Codes, and implantation/replacement codes such as 64582 and 61886 are listed. The policy also notes that HSAT and PSG testing criteria pre‑ and post‑implant are covered within the Sleep Disordered Breathing Diagnosis and Treatment Guidelines.